Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
IPO Year: 2006
Exchange: NASDAQ
Website: cytocom.com
3 - Statera Biopharma, Inc. (0001318641) (Issuer)
4 - Statera Biopharma, Inc. (0001318641) (Issuer)
DEFR14A - Statera Biopharma, Inc. (0001318641) (Filer)
DEF 14A - Statera Biopharma, Inc. (0001318641) (Filer)
PRE 14A - Statera Biopharma, Inc. (0001318641) (Filer)
8-K - Statera Biopharma, Inc. (0001318641) (Filer)
8-A12G - Statera Biopharma, Inc. (0001318641) (Filer)
8-K - Statera Biopharma, Inc. (0001318641) (Filer)
DEF 14A - Statera Biopharma, Inc. (0001318641) (Filer)
PRE 14A - Statera Biopharma, Inc. (0001318641) (Filer)
8-K - Statera Biopharma, Inc. (0001318641) (Filer)
10-Q - Statera Biopharma, Inc. (0001318641) (Filer)
FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the appointment of Certified Public Accountants, BF Borgers CPA PC as the Company's independent accountant to audit the balance sheet of the Company as of December 31, 2021, and the related statements of operations, stockholders' equity and income, and cash flows for the period ended December 31, 2021. About Statera BiopharmaStatera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company develo
Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t
WEST PALM BEACH, Fla., April 11, 2024 /PRNewswire/ -- Anthony, Linder & Cacomanolis, PLLC is proud to announce that Partner Craig D. Linder has been selected to the 2024 Top 50 Lawyers in America list for securities law. This prestigious accolade is part of the 10th annual list honoring a select group of 50 lawyers who have demonstrated outstanding leadership and success within the securities law community in the Americas. America's Top 50 Lawyers identifies and highlights the accomplishments of the nation's most distinguished and skilled attorneys in all fields of practice of law. Only 50 lawyers in each state will receive this honor and be selected for this esteemed membership. This hon
FORT COLLINS, Colo., March 15, 2023 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (OTCPK:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has entered into a non-binding letter of intent (the "LOI") with Worksite Labs, Inc. ("WSL"), setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL (the "Proposed Transaction"). "We believe the proposed merger could e
FORT COLLINS, CO / ACCESSWIRE / January 24, 2023 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, is pleased to announce it has completed the application process for moving off the OTC Pink Sheets and uplisting to the OTCQB® Venture Marketplace. The application process will not guarantee acceptance of the Company's submission by OTC MARKETS from the PINKS to OTCQB. This is the Company's first step in its pursuit to regain its listing on the NASDAQ exchange.The Company believes that the move to the OTCQB will provide enhanced investor benefits,
FORT COLLINS, CO / ACCESSWIRE / October 27, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that, by decision dated October 26, 2022, a Nasdaq Hearings Panel granted the Company's request for continued listing on The Nasdaq Capital Market ("Nasdaq"), subject to the Company's satisfaction of certain interim milestones and, ultimately, the Company's compliance with all applicable criteria for continued listing on Nasdaq, including the $1.00 bid price and $2.5 million stockholders' equity requirements, by January 31, 2023.Ab
FORT COLLINS, CO / ACCESSWIRE / October 21, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the "Q1 Form 10-Q") with the Securities and Exchange Commission (the "SEC"). With the Q1 Form 10-Q now on file, the Company is focused on the completion and filing of its Form 10-Q for the quarter ended June 30, 2022.Additionally, the Company entered into an agreement ("Agreement") with Silverback Capital Corporation ("Silverback Capital"
FORT COLLINS, CO / ACCESSWIRE / October 17, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the signing of a binding Memorandum of Understanding ("MOU") with Holobeam Technologies, Inc. ("Holobeam"). Holobeam is the world leader in creating the next generation of holographic medical imaging and therapeutic technologies for the early detection and treatment of cancer and other diseases using their newly patented Holographic Energy Teleportation (HET) technology. This breakthrough technology will enable cancer detection yea
FORT COLLINS, CO / ACCESSWIRE / October 6, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audit of the Company's financial statements for fiscal 2021 is complete and that the Company today filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "Form 10-K") with the Securities and Exchange Commission (the "SEC"). With the Form 10-K now on file, the Company is focused on the completion and filing of the Forms 10-Q for the quarterly periods ended March 31, June 30, and September 30, 2
FORT COLLINS, CO / ACCESSWIRE / September 9, 2022 / Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced - as disclosed via the Company's Current Report on Form 8-K as filed with the Securities and Exchange Commission (the "SEC") on Friday, September 9, 2022 - that on September 1, 2022, the Company was notified by the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC that its common stock was subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company timely
NEW YORK, Aug. 26, 2022 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading resumed in Statera Biopharma, Inc. (NASDAQ:STAB) today, August 26, 2022 at 7:10 a.m. Eastern Time. Trading in the company's stock was halted on August 25, 2022 at 11:01:52 a.m. Eastern Time. For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotesSM on the Nasdaq® Web site. For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. NDAQO Nasdaq Media Contact:Sophia [email protected]
Broad licensing agreement accelerates Tivic's transformation into a diversified therapeutics company, adds late-stage immunotherapeutic to clinical pipeline. Potential for FDA approval within 24 months. Tivic Health Systems, Inc., (NASDAQ:TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC:STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod™ for the treatment of acute radiation syndrome (ARS). In addition, the company has acquired an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta™. This broad licensing agreement establishes Tivic as a diversified t
FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company has filed a Form 12b-25 with the U.S. Securities and Exchange Commission to extend until April 15, 2022 the due date for filing the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Statera Biopharma has been unable to complete its financial statements for the full year 2021 due to a delay experienced in completing its financial statements and other disclosures in t
Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB) (the "Company" or "Statera Biopharma"), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Thursday, March 31, 2022, at 5:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and full year ended December 31, 2021. Conference Call & Webcast Details DateThursday, March 31, 2022Time5:30 p.m. ETLive Audio Webcasthttps://edge.media-server.com/mmc/p/yffrdzzpTeleph
FORT COLLINS, Co., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today reported important corporate events and financial results for the third quarter ended September 30, 2021. Statera Biopharma was formerly known as Cleveland BioLabs, Inc. and merged with Cytocom Inc. on July 27, 2021. "We are pleased with our operational progress to integrate the portfolio and advance our clinical programs as we prepare to initiate several clinical trials during 2022, including a pivotal Phase 3 trial for our lead drug candidate, STAT-201, in pediatri
FORT COLLINS, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced today that the Company will host a conference call and live audio webcast on Monday, November 15, 2021, at 5:30 p.m. ET, to discuss its corporate and financial results for the third quarter of 2021. Conference Call & Audio Webcast Details Date Monday, November 15, 2021Time 5:30 p.m. ET Telephone Access: U.S. and Canada 800-937-6813Telephone Access: International 213-660-0853Access Code for All Callers 2973387Live Audio Webcast https://edge.media-server.com/mmc/